FDA clears Immucor's new blood screening system
This article was originally published in Clinica
Immucor's fourth-generation automated blood testing instrument, Neo, has received 510(k) clearance from the US FDA. The device is designed to help high-throughput blood banks and laboratories increase productivity, performance and flexibility, Norcross, Georgia-based Immucor claims. Neo can process up to 224 samples at once, and operators can add samples at any time. Its test menu includes ABO/Rh blood typing, and antigen and antibody screening. The firm already markets other blood screening systems, including the Galileo and Galileo Echo.